



Potential neuroprotective benefits of erythropoietin during
experimental hypothermic circulatory arrest
Pekka Romsi, MD,a Erkka Ro¨nka¨, MS,a Kai Kiviluoma, MD, PhD,b Vilho Vainionpa¨a¨, MD, PhD,b
Jorma Hirvonen, MD, PhD,c Ari Mennander, MD, PhD,a Matti Pokela, MS,a Fausto Biancari, MD, PhD,a
Jussi Rimpila¨inen, MD, PhD,a and Tatu Juvonen, MD, PhDa
Objective: Recent studies have shown that erythropoietin protects neurons from
glutamate toxicity and ischemia. This study was performed to evaluate the potential
neuroprotective effect of erythropoietin during experimental hypothermic circula-
tory arrest.
Methods: Twenty pigs were randomized to receive intravenously either 500 IU/kg
recombinant human erythropoietin or saline before a 75-minute period of hypother-
mic circulatory arrest at an intracerebral temperature of 18°C.
Results: After the administration of erythropoietin, its concentration in the cerebrospinal
fluid increased 4.5-fold 8 hours after the start of rewarming, whereas it did not increase
in control animals. The 7-day survival rate was 60% in the erythropoietin group and
70% in the control group (P  1.0). No significant differences were observed between
the study groups in terms of electroencephalography, behavioral score, and histopatho-
logic score. The erythropoietin group had higher vascular resistance and mean arterial
pressure values, lower intracerebral concentrations of glutamate and glycerol, higher
brain tissue oxygen tension, and lower apoptotic index.
Conclusions: Administration of 500 IU/kg erythropoietin intravenously before hy-
pothermic circulatory arrest was followed by an increased erythropoietin concen-
tration in the cerebrospinal fluid. Although previous studies have demonstrated
neuroprotective effects of erythropoietin during brain ischemia, the present study,
using a chronic porcine model, failed to show any significant benefit after admin-
istration of erythropoietin in terms of mortality or brain histopathology. Lower
intracerebral concentrations of glutamate and glycerol, higher brain tissue oxygen
tension, and lower apoptotic index observed in the erythropoietin group, however,
suggest that a distinct neuroprotective effect of erythropoietin might be achieved at
different dosages and timing of administration.
Erythropoietin (EPO) is a glycoprotein first characterized as a hema-topoietic growth factor produced by the kidney. Recent studies haveshown that astrocytes also produce EPO in a hypoxia-induciblemanner, and that EPO receptors are expressed in neurons.1-4 There isevidence that EPO protects primary cultured neurons from N-meth-yl-D-aspartate receptor–mediated glutamate toxicity,2 and that intra-
cerebroventricular3,5-7 and systemic administration1,7,8 of recombinant human EPO
(r-Hu-EPO) reduces neuronal ischemic injury. Because these in vivo and in vitro
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stroke model studies have provided convincing evidence on
the neuroprotective effect of systemically administered
EPO, we planned the present study to evaluate its potential
neuroprotective efficacy in a chronic porcine model of hy-
pothermic circulatory arrest (HCA).
Materials and Methods
Twenty female juvenile pigs (age, 8-10 weeks) of a native stock
were randomly assigned to receive either 500 IU/kg r-Hu-EPO or
placebo as an intravenous injection before a 75-minute period of
HCA at an intracerebral temperature of 18°C.
Preoperative Management
All animals received humane care in accordance with the “Prin-
ciples of Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the Care and Use
of Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published by
the National Academy Press, revised 1996. The study was ap-
proved by the Research Animal Care and Use Committee of the
University of Oulu.
Anesthesia and Hemodynamic Monitoring
Anesthesia was induced with ketamine hydrochloride (10 mg/kg
administered intramuscularly) and midazolam (1 mg/kg adminis-
tered intramuscularly). A peripheral venous catheter was inserted
into the right ear for administration of drugs and to maintain fluid
balance with Ringer acetate. Anesthesia was deepened with thio-
pental sodium (125-250 mg administered intravenously), and pan-
curonium bromide (4 mg administered intravenously) was given
for muscular paralysis. Cefuroxime, 1.5 g, was given as antibiotic
prophylaxis at anesthesia induction, 8 hours after the start of
rewarming, and before extubation.
After endotracheal intubation, the animals were maintained on
positive-pressure ventilation with 50% oxygen, and anesthesia was
maintained with isoflurane (1.2%-1.3%). Electrocardiographic
monitoring was started. An arterial catheter was positioned into the
left femoral artery for arterial pressure monitoring and blood
sampling. A thermodilution catheter (CritiCath, 7F; Ohmeda
GmbH & Co, Erlangen, Germany) was placed through the left
femoral vein to allow blood collecting, pressure monitoring in the
pulmonary artery, and recording of blood temperature and cardiac
output. A 10F catheter was placed in the urinary bladder for
monitoring urine output. Blood, rectal, esophageal, epidural, and
intracerebral temperatures were monitored continuously.
Brain Microdialysis and Intracerebral Monitoring
A temperature probe was placed into the epidural space through a
cranial hole made in the left side anteriorly to the coronal suture.
A catheter for the measurement of intracerebral tissue oxygen
partial pressure (Revodoxe Brain Oxygen Catheter-Micro-Probe,
REF. CC1.SB; GMS, Mielkendorf, Germany) was inserted
through a hole located at the right side anteriorly to the coronal
suture. Another temperature probe (Thermocouple Temperature
Catheter-Micro-Probe, REF. C8.B, GMS) for the measurement of
intracerebral temperature, together with an intracranial pressure-
monitoring catheter (Codman Micro-Sensor ICP Transducer; Cod-
man & Shurtleff, Inc, Raynham, Mass), were placed through a hole
located at the left side posteriorly to the coronal suture. Intracere-
bral temperature and brain tissue oxygen partial pressure were
monitored with the Licox CMP Monitor (GMS). Intracranial pres-
sure was monitored with the Codman ICP Express Monitor (Cod-
man & Shurtleff, Inc).
The microdialysis catheter (CMA 70; CMA/Microdialysis,
Stockholm, Sweden) was placed into the brain cortex to a depth of
15 mm below the dura mater through a hole located at the right
side posteriorly to the coronal suture. The catheter was connected
to a 2.5-mL syringe placed into a microinfusion pump (CMA 106,
CMA/Microdialysis) and perfused with Ringer solution (Perfusion
Fluid CNS, CMA/Microdialysis). Samples were collected at dif-
ferent time points. The concentrations of cerebral tissue glucose,
lactate, glutamate, and glycerol were measured immediately after
collection with a microdialysis analyzer (CMA 600, CMA/Micro-
dialysis) by using ordinary enzymatic methods.
Electroencephalographic Monitoring
Cortical electrical activity was registered by 4 stainless-steel screw
electrodes of 5 mm in diameter implanted into the skull over the
parietal and frontal areas of the cortex by using a digital electro-
encephalography recorder (Nervus, Reykjavik, Iceland) and an
amplifier (Magnus EEG 32/8, Reykjavik, Iceland). Sampling fre-
quency was 256 Hz, and bandwidth was 1.6 to 70 Hz. All 4
electroencephalographic electrodes were referenced to another
screw electrode, which, together with a ground screw electrode,
was implanted over the frontal sinuses.
The isoflurane level was adjusted so that electroencephalogra-
phy showed a steady burst-suppression pattern. Then isoflurane
end-tidal concentration was kept at this steady level until the end
of monitoring. An electroencephalogram was recorded for 10
minutes before the injection of r-Hu-EPO/saline to make the first
baseline recording of steady burst-suppression activity and for
another 10 minutes between the injection and the cooling period to
make the second baseline recording. After HCA, electroencepha-
lographic recording was restarted and continued until extubation.
The duration of bursts were measured from 5-minute electroen-
cephalographic samples at 1-hour intervals with a custom-made
automatic analysis program. Artifact periods were excluded from
each 5-minute sample, and after that, the sum of burst durations
was counted as a percentage of the sum of artifact-free electroen-
cephalography in this sample. This percentage was used as a
measure of electroencephalographic activity in the analysis.
Cardiopulmonary Bypass
Through a right thoracotomy in the fourth intercostal space, the
right thoracic vessels were ligated, the pericardium was opened,
and the heart and great vessels were exposed. A membrane oxy-
genator (Midiflow D 705; Dideco, Mirandola, Italy) was primed
with 1 L of Ringer acetate and heparin (5000 IU). After systemic
heparinization (500 IU/kg), the ascending aorta was cannulated
with a 16F arterial cannula, and the right atrial appendage was
cannulated with a single 24F atrial cannula. Nonpulsatile cardio-
pulmonary bypass (CPB) was initiated with 100% oxygen (main-
tained during cooling and rewarming periods) at a flow rate of 100
mL  kg1  min1, and the flow was adjusted to maintain a per-
fusion pressure of 50 mm Hg. A 12F intracardiac sump cannula
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was positioned in the left ventricle through the apex of the heart for
decompression of the left side of the heart during CPB. A heat
exchanger was used for core cooling. The pH was maintained with
alpha-stat principles at 7.40 0.05, with an arterial carbon dioxide
tension of 4.0 to 5.0 kPa uncorrected for temperature.
Drug Administration
Recombinant human EPO is a human 165-amino-acid glycopro-
tein with a molecular weight of 32 to 40 kd. It is manufactured by
using recombinant DNA technology. It contains the identical
amino acid sequence and has the same biologic activity as isolated
natural EPO.9 The r-Hu-EPO used was epoetin  (Neo-Recormon;
Roche Co, Basel, Switzerland), which was formulated as a sterile,
colorless liquid in distilled water (100,000 IU [830 g]/5 mL). The
drug dosage was 500 IU/kg. Before the injection, the drug was
diluted with isotonic sodium chloride to obtain a total volume of 5
mL. The placebo consisted of a corresponding volume of isotonic
sodium chloride. A slow 5-mL intravenous injection was given in
a double-blinded fashion according to the randomization protocol.
Experimental Protocol
After baseline measurements and 60 minutes before the start of
cooling perfusion, the r-Hu-EPO/placebo was given to the animals.
A second baseline electroencephalogram was recorded after that,
and the cannulation of the heart and aorta was done. A cooling
period of 60 minutes was carried out to attain an intracerebral
temperature of 18°C. Then a 75-minute period of HCA was
started. The ascending aorta was crossclamped just distal to the
aortic cannula, and cardiac arrest was induced by injecting potas-
sium chloride (3 g) through the aortic cannula. Topical cardiac
cooling with ice slush was begun and maintained throughout the
HCA period. During HCA, the epidural and intracerebral temper-
atures were maintained at a level of 18°C with ice packs placed
over the head. After 75 minutes of HCA, rewarming was started.
The animals were rewarmed to a core temperature of 37°C during
60 minutes of reperfusion, and this temperature was maintained
until the end of the experiment. The temperatures were regulated
with heat-exchanger mattresses, heating lamps, and ice packs.
During rewarming, the left ventricular sump cannula was re-
moved, and furosemide (40 mg), mannitol (15 g), methylpred-
nisolone (80 mg), lidocaine (40-160 mg), and calcium glubionate
(1375 mg) were administered. After weaning from CPB, cardiac
support was provided with dopamine. The animals were kept in
isoflurane anesthesia, and they were ventilated with 100% oxygen
until 2 hours after the start of rewarming and after that with 50%
oxygen until the following morning (18 hours after the start of
rewarming), when they were extubated and moved to a recovery
room.
During the experiment, hemodynamic and metabolic measure-
ments (pulse rate, systemic and pulmonary arterial pressures, cen-
tral venous pressure, pulmonary capillary wedge pressure, cardiac
output, intracranial pressure, intracerebral tissue oxygen partial
Figure 1. Intracerebral temperatures in pigs during the experimental protocol. Values are expressed as medians
with interquartile ranges (25th-75th percentile).
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pressure, temperatures, arterial and venous pH, oxygen and carbon
dioxide partial pressures, oxygen saturation, oxygen concentration,
hematocrit, hemoglobin, sodium, potassium, and glucose [Ciba-
Corning 288 Blood Gas System; Ciba-Corning Diagnostic Corp,
Medfield, Mass]; lactate [YSI 1500 analyzer; Yellow Springs
Instrument Co, Yellow Springs, Ohio]; leukocyte differential
count [Cell-Dyn analyzer; Abbot, Santa Clara, Calif]; and creatine
kinase [CK] and its isoenzymes [CK-MM, CK-MB, CK-BB, Hy-
drasys LC-electrophoresis, Hyrys-densitometry; Sebia, France])
were recorded continuously or at baseline; at the end of cooling
(immediately before institution of HCA); at 40 minutes, 2 hours, 4
hours, and 8 hours after the start of rewarming; and before extu-
bation.
EPO Assay
EPO concentrations were measured from samples of plasma col-
lected before drug administration (baseline), at the end of cooling,
40 minutes and 8 hours after the start of rewarming, and at
extubation. EPO concentrations in the cerebrospinal fluid were
measured after collecting the liquid from the lumbar cerebrospinal
space before drug administration, 8 hours after the start of rewarm-
ing, and at extubation. Only those samples free from blood were
accepted for the analysis.
EPO concentrations were determined by using a commercially
available bioassay (2nd IRP EPO, human, for bioassay NIBSC
Code: 67/343) by Medix Laboratories (Espoo, Finland). The lower
limit of detection was 8.0 U/L.
Postoperative Evaluation
Postoperatively, all the animals were evaluated daily by an expe-
rienced observer who was blinded to the study group by using a
species-specific quantitative behavioral score. The assessment
quantified mental status (0  comatose, 1  stuporous, 2 
depressed, and 3  normal), appetite (0  refuses liquids, 1 
refuses solids, 2  decreased, and 3  normal), and motor func-
tion (0  unable to stand, 1  unable to walk, 2  unsteady gait,
and 3  normal). Numeric summing of these functions provides a
final score, with the maximum (score of 9) reflecting apparently
normal neurologic function, and lower values indicating substan-
tial brain damage.
Perfusion Fixation
Each surviving animal was electively killed on the seventh post-
operative day. Immediately after intravenous injection of pento-
barbital (60 mg/kg) and heparin (500 IU/kg), the thoracic cavity
was opened, and the descending thoracic aorta was clamped.
Ringer solution (1 L) was infused through the ascending thoracic
aorta and through the upper body, and blood was suctioned from
the superior vena cava until the perfusate was clear of blood. Then
10% formalin solution (1 L/15 min) was perfused through the
brain in the same manner to accomplish a perfusion fixation.
Immediately thereafter, the entire brain was harvested, weighed,
and immersed in 10% neutral formalin. The same method of
fixation procedure was carried out in those animals that died before
the seventh postoperative day.
Histopathologic Analysis
The brain was allowed to fix for 1 week en bloc. Thereafter,
3-mm-thick coronal samples were sliced from the left frontal lobe,
thalamus (including the adjacent cortex), and hippocampus (in-
cluding the adjacent brainstem and temporal cortex), and sagittal
samples from the posterior brainstem (medulla oblongata and
pons) and cerebellum were obtained. The specimens were fixed in
fresh formalin for another week. After fixation, the samples were
processed as follows: rinsing in water for 20 minutes and immer-
sion in 70% ethanol for 2 hours, 94% ethanol for 4 hours, and
Figure 2. Daily score indicating behavioral recovery after 75 minutes of HCA. A score of 9 indicates essentially
complete recovery.
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absolute ethanol for 9 hours. Then the specimens were kept for 1
hour in an absolute ethanol-xylene mixture and for 4 hours in
xylene and embedded in warm paraffin for 6 hours. The specimens
were sectioned at 6 m and stained with hematoxylin and eosin.
The sections of the brain specimens of each animal were screened
by an experienced senior pathologist (J.H.) unaware of the exper-
imental design and the identity and fate of individual animals.
Each section was carefully examined for the presence or absence
of any ischemic or other kinds of tissue damage.
The signs of injury were scored as follows: 1 (slight edema,
with dark or eosinophilic neurons or cerebellar Purkinje cells); 2
(moderate edema, with at least 2 hemorrhagic foci in the section);
and 3 (severe edema, with several hemorrhagic foci and infarct
foci [local necrosis]). The total regional score was the sum of the
scores in each specific brain area (cortex, thalamus, hippocampus,
posterior brainstem, and cerebellum). A total histopathologic score
was calculated by summing all the regional scores to allow semi-
quantitative comparisons between the animals.
Evaluation of Apoptosis
Brain tissue specimens were further evaluated for the extent of
apoptosis by means of 3 end-labeling of apoptotic DNA (TUNEL
procedure) with the ApopTag in situ Apoptosis Detection Kit
(Oncor, Gaithersburg, Md). A cell was defined as apoptotic if the
whole nuclear area showed a positive brown reaction, whereas
apoptotic bodies appeared as small positively labeled globular
fragments. All positively labeled cells and bodies showed the
morphologic criteria for apoptosis (ie, nuclear condensation, cell
shrinkage, cytoplasmic budding to form membrane-bound frag-
ments, and detachment from surrounding cells). The number of
apoptotic cells and bodies within the infarct area was counted in at
least 5 high-power fields (magnification 40). The quantity of
apoptotic cells and bodies (ie, apoptotic index [AI%]) was ex-
pressed as a percentage of the whole cell population within the
infarct area.
Statistical Analysis
Statistical analysis was performed with SPSS software (SPSS
version 10.0; SPSS Inc, Chicago, Ill). Values are expressed as the
median with interquartile ranges (25th-75th percentile). Difference
in survival outcome in the study groups was evaluated with the
Fisher exact test. Differences between the groups were determined
by using the t test or the Mann-Whitney test. Repeated-measures
analysis of variance was used, and the results of the tests of
between-subject effects were reported.
Results
Comparability of the Groups
The median weight of the pigs was 27.2 kg (interquartile
range, 25.8-29.5 kg) in the EPO group and 26.1 kg (inter-
quartile range, 25.0-28.7 kg) in the control group (P  .49).
The median CPB cooling time was 60.0 minutes (interquar-
tile range, 60.0-61.0 minutes) in the EPO group and 60.5
minutes (interquartile range, 60.0-61.5 minutes) in the con-
trol group (P  .64). The median CPB rewarming time was
63.5 minutes (interquartile range, 61.8-68.0 minutes) in the
EPO group and 62.5 minutes (interquartile range, 60.8-64.8
minutes) in the control group (P  .24). The median total
CPB time was 123.5 minutes (interquartile range, 122.0-
128.0 minutes) in the EPO group and 124.0 minutes (inter-
quartile range, 121.0-127.0 minutes) in the control group
(P  .39). During the experiment, rectal, esophageal, epi-
dural, and cerebral temperatures did not differ between the
groups (the latter is shown in Figure 1).
Plasma and Cerebrospinal Fluid EPO Concentrations
The median baseline EPO concentration in plasma was 20.1
U/L (17 and 23 U/L, n  2). After the intravenous injection
of r-Hu-EPO, the median EPO concentrations in plasma
were 1397 U/L (range, 1300-1456 U/L) at the end of cool-
ing (n 3), 1422 U/L (1378 U/L and 1465 U/L) 40 minutes
after the start of rewarming (n  2), 1541 U/L (1436 U/L
and 1646 U/L) 8 hours after the start of rewarming (n  2),
and 1068 U/L at extubation (n  1).
The median baseline EPO concentration in the cerebro-
spinal fluid was 8.2 U/L (range, 7.2-9.8 U/L) in the EPO
group (n  5) and 7.7 U/L (range, 7.2-9.1 U/L) in the
control group (n 5). Eight hours after the start of rewarm-
ing, the concentration was 36.7 U/L (range, 34.7-92.9 U/L)
in the EPO group (n  3) and 8.4 U/L (range, 6.7-9.8 U/L)
in the control group (n  4). At extubation, the concentra-
tion was 14.5 U/L (11.5 U/L and 17.5 U/L) in the EPO
group (n  2) and 8.4 U/L (range, 7.4-8.8 U/L) in the
control group (n  3).
Mortality and Behavioral Outcome
The 7-day survival rate was 60% in the EPO group and 70%
in the control group (P  1.0). There were no significant
differences between the study groups in the overall postop-
erative behavioral scores (P  .85, Figure 2). Among those
animals that survived all 7 days, the scores were similar
between the groups (P  .53).
Hemodynamic and Metabolic Data
There were some differences between the study groups in
terms of hemodynamics (Figure 3). Vascular resistance was
higher in the EPO group from the fourth hour after the start
of rewarming until extubation. The EPO group had signif-
icantly higher mean arterial pressure values (P  .04, tests
of between-subjects effects) throughout the experiment. The
cardiac index tended to be lower in the EPO group during
the postoperative period, which led to a significantly lower
oxygen delivery rate at extubation (P  .04). However,
there were no significant differences between the groups in
the amount of dopamine administered (data not shown).
The study groups did not differ significantly in terms of
pH, oxygen and carbon dioxide tension, mixed venous
oxygen saturation, oxygen consumption, total leukocyte and
neutrophil counts, and venous concentrations of glucose,
lactate, sodium, and potassium (data not shown).
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Measurements of serum concentrations of total CK
showed that this parameter tended to be higher from the end
of cooling until the fourth hour after the start of rewarming
among pigs that received EPO. The difference in total CK
levels was related to the difference in CK-MM levels be-
cause the concentrations of CK-MB and CK-BB were sim-
ilar between the study groups (data not shown).
Intracranial Measurements
Intracranial measurement data are presented in Figure 4.
Intracranial microdialysis showed some differences be-
tween the study groups. Brain glucose tended to be higher in
the control group from the 5-hour until the 12-hour interval
after the start of rewarming. Brain glutamate was higher in
the control group throughout the postoperative period. This
difference was statistically significant at 6-hour (P  .03)
and 7-hour (P  .03) intervals after the start of rewarming.
Also, brain glycerol tended to be higher in the control group
during the first postoperative hours. However, brain lactate
levels did not differ between the study groups.
Brain tissue oxygen partial pressure tended to be higher
in the EPO group during the last hours of the experiment.
Intracranial pressure levels were similar in both groups
throughout the experiment.
Electroencephalographic Findings
The electroencephalographic findings before and after the
intravenous administration of r-Hu-EPO were similar, thus
suggesting that the drug did not have any effect on electro-
encephalographic activity. The median rate of electroen-
cephalographic burst recovery from the start of rewarming
until extubation was similar in both groups. At the 7-hour
interval after the start of rewarming, the median electroen-
cephalographic burst-suppression ratios were close to 100%
in both groups (ie, electroencephalography was continuous
and without suppressions).
Figure 3. Hemodynamic parameters. Values are expressed as medians with interquartile ranges (25th-75th
percentile). P values are for the EPO group versus the control group. MAP, Mean arterial pressure (in this
parameter, P value between groups is .04, according to the tests of between-subjects effects).
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Figure 4. Results of brain microdialysis, intracranial pressure, and brain tissue oxygen partial pressure measure-
ments. Values are expressed as medians with interquartile ranges (25th-75th percentile). P values are for the EPO
group versus the control group.
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Histopathologic Data
The total histopathologic score among the animals of the
EPO group did not differ significantly from those of
control animals (11.3 vs 10.9, respectively; P  .8).
Also, the scores from different brain regions (cortex,
thalamus, hippocampus, posterior brainstem, and cere-
bellum) did not differ significantly between the groups
(Table 1).
Figure 5. Brain cellular apoptotic indexes in pigs surviving for 7 days that underwent brain infarction (P .06, EPO
group vs control group).

















EPO 1 7 5 1 2 1 1 10
2 7 5 1 2 1 0 9
3 7 2 1 2 1 1 7
4 1 5 4 1 3 3 16
5 1 6 2 1 4 4 17
6 1 6 5 3 4 4 22
7 7 5 1 1 1 1 9
8 1 5 4 1 1 1 12
9 7 2 1 1 1 0 5
10 7 2 1 2 1 0 6
Mean 4.6 4.3 2.1 1.6 1.8 1.5 11.3
Control 1 7 5 2 2 3 2 14
2 7 5 1 2 0 0 8
3 7 7 1 2 1 1 12
4 7 8 2 4 1 1 16
5 1 2 1 1 1 1 6
6 2 4 4 3 3 4 18
7 7 1 0 1 0 1 3
8 7 2 1 2 1 1 7
9 7 2 1 1 1 0 5
10 1 6 3 3 4 4 20
Mean 5.3 4.2 1.6 2.1 1.5 1.5 10.9
Signs of brain ischemic injury were scored as follows: 1 (slight edema, with dark or eosinophilic neurons or cerebellar Purkinje cells); 2 (moderate edema,
with at least 2 hemorrhagic foci in the section); and 3 (severe edema, with several hemorrhagic foci and infarct foci [local necrosis]). The total score is
the sum of the scores for each specific brain area.
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Thirteen pigs survived 7 days. Among these pigs, there were
4 animals in the EPO group and 5 in the control group that
had brain infarction. The mean apoptotic index was 0 in the
EPO group and 0.99 in the control group (P  .06, Figures
5 and 6).
Discussion
Recent studies demonstrated that EPO has several biologic
activities other than the hematopoietic one. EPO mRNA and
receptors have been found in brain tissue, and the neuro-
protective effect of r-Hu-EPO has been demonstrated in
both in vitro and in vivo stroke models, as well in brain
injury after trauma, subarachnoid hemorrhage, inflamma-
tion, and seizures.10,11 EPO is likely to be produced by
astrocytes in a hypoxia-inducible manner, whereas exoge-
nous EPO could reach the neurons only through a damaged
blood-brain barrier.4,12 However, Brines and colleagues1
observed that EPO and its receptors are abundantly ex-
pressed in brain capillaries, thus probably providing a route
for circulating EPO to enter the brain. They also observed
that biotinylated r-Hu-EPO crosses the blood-brain barrier
and that intraperitoneal injection of r-Hu-EPO was associ-
ated with an increase in EPO concentrations in the cerebro-
spinal fluid.
The mechanisms underlying the neuroprotective effects
of EPO are not clear. EPO can rescue cells from death
through modulation of apoptosis,5,8,13,14 necrosis, inflamma-
tory injury,1,8 or neuronal excitability.1 It has been sug-
gested that EPO contributes to nitric oxide metabolism and
activates Ca2 channels2,5,7,15 and that EPO has a specific
neurotrophic activity.8,16
The present study did not show any striking neuropro-
tective effects of EPO in an experimental model of HCA.
However, brain glutamate and glycerol levels and brain
tissue oxygen tension tended to be more favorable in the
EPO group, thus suggesting that EPO might have some
neuroprotective effects after global brain ischemic injury.
Interestingly, the apoptotic activity in the infarct area was
lower among the EPO-treated animals 7 days after the
ischemic event. This finding mirrored other observations on
EPO-induced inhibition of apoptosis.5,8,13,14 Siren and co-
workers8 suggested that EPO inhibits the ischemia-induced
neuronal cell apoptosis through activation of the bcl family
of antiapoptotic genes, thus activating the specific protein
kinases to promote cell survival.
The results of the present study could have been affected
by the timing of EPO administration. Calapai and associ-
ates7 observed in their stroke model that systemic pretreat-
ment with r-Hu-EPO 60 minutes before ischemia failed to
improve brain ischemic injury, whereas the administration
of the drug immediately after the ischemia produced bene-
ficial effects. However, Brines and colleagues1 demon-
strated a similar effect of neuroprotection between preisch-
emic and postischemic administration of r-Hu-EPO.
It is possible that the EPO concentrations achieved in the
cerebrospinal fluid after a single intravenous dose are not
enough to provide adequate brain protection in the present
animal model of HCA. Daily administration of EPO during
the 7 postoperative days would have probably strengthened
the possible neuroprotective effect, hypothetically by means
of a further reduction of cellular apoptosis.
The use of EPO in this study was associated with an
increase in vascular resistance, which resulted in higher
mean arterial pressure values, as well as in a decreased
cardiac index and oxygen delivery rate. An increase of
hematocrit,17 endothelin production,18 and tissue renin-
angiotensin activity,19 as well as a direct vasopressor action
of EPO,20 have been suggested to be implicated in the
pathogenesis of hypertension during long-term administra-
Figure 6. Brain tissue sections after 3 end-labeling of apoptotic
DNA (TUNEL) of an animal that received r-Hu-EPO preoperatively
(a) and a control animal (b). (Original magnification 40.) No
apoptotic staining is present in the EPO-treated animal, whereas
several brown apoptotic cells can be seen in the control animal.
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tion of EPO. It is possible that, in the present study, a direct
vasoconstrictive effect of EPO could have also affected the
cerebral blood flow, and this might have masked the possi-
ble neuroprotective effect of the drug.
In conclusion, the administration of 500 IU/kg r-Hu-EPO
intravenously before experimental HCA was followed by a
long-lasting increase of EPO concentration in the cerebro-
spinal fluid. Although in vitro and in vivo stroke model
studies have demonstrated neuroprotective effects of EPO
during brain ischemia, the present study, using a chronic
porcine model of HCA, failed to show any significant ben-
efit after administration of r-Hu-EPO in terms of mortality,
electroencephalographic findings, and brain histopathologic
findings. Lower intracerebral concentrations of glutamate
and glycerol, higher brain tissue oxygen partial pressure,
and lower apoptotic index observed among the EPO-treated
animals, however, suggest that a distinct neuroprotective
effect of r-Hu-EPO might be achieved at different dosages
and timing of administration.
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